» Articles » PMID: 21382156

Genes and Hepatitis C: Susceptibility, Fibrosis Progression and Response to Treatment

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2011 Mar 9
PMID 21382156
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C virus contact and infection show three different phenotypes: spontaneous viral clearance (SVC), chronic hepatitis C (CHC) and sustained virological response (SVR) following antiviral treatment. Many factors, including genetics, influence the evolution of these three phenotypes. We performed a literature search (PubMed) up to 31 January 2010 without language restriction to identify relevant studies on genes and hepatitis C. Additional studies were sought by reviewing the reference lists of the identified articles. Meta-analysis (using Meta-disk 1.4) was conducted to evaluate the association of single nucleotide polymorphism (SNP) in the IL28B region and SVR. The candidate gene approach showed strong relationships between human leucocyte antigen class II (DQB1(*) 0301 and DRB1(*) 1101) and SVC. A cirrhosis risk score involving 7 SNPs has been validated recently. The set of odds ratios of studies demonstrated an association between SNP (rs12987960/rs8099917) in the IL28B and SVR in CHC treated with peginterferon plus ribavirin (OR: 4.6; 95% CI: 2.9-7.3). The overall distribution of protective allele correlated with ethnic differences in SVR (Asians, Europeans, Hispanic and Afro-Americans) together with SVC, but not with fibrosis stage or viral load. These polymorphisms did not influence SVR in very-easy-to-treat patients such as genotype 2/3, rapid virological responders or patients with acute hepatitis C. While the genetic fingerprint for fibrosis progression remains elusive, IL28b polymorphism predicts SVC and SVR. However, nearly half of patients achieving SVR did not show favourable genotype. Further genetic signals are warranted to complete the puzzle of factors influencing hepatitis C.

Citing Articles

Exportin 4 DNA promoter methylation in liver fibrosis.

Pan Z, Bayoumi A, Metwally M, George J, Eslam M PLoS One. 2024; 19(5):e0302786.

PMID: 38722973 PMC: 11081319. DOI: 10.1371/journal.pone.0302786.


Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression.

Dhaouadi T, Riahi A, Ben Abdallah T, Gorgi Y, Sfar I Int J Immunopathol Pharmacol. 2024; 38:3946320241240705.

PMID: 38520313 PMC: 10960981. DOI: 10.1177/03946320241240705.


Breakthroughs in hepatitis C research: from discovery to cure.

Manns M, Maasoumy B Nat Rev Gastroenterol Hepatol. 2022; 19(8):533-550.

PMID: 35595834 PMC: 9122245. DOI: 10.1038/s41575-022-00608-8.


Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population.

Rauff B, Amar A, Chudhary S, Mahmood S, Tayyab G, Hanif R Arch Virol. 2021; 166(4):1047-1056.

PMID: 33528661 DOI: 10.1007/s00705-020-04901-2.


A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms.

Sharkawy R, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M Sci Rep. 2019; 9(1):1439.

PMID: 30723271 PMC: 6363805. DOI: 10.1038/s41598-018-35736-2.